RespiraCorp Australia announces their partnering strategy with sleep clinics for distribution of the company’s OTC sleep innovation SleepQ+.
Connecting With The Elusive Undiagnosed OSA Population
While CPAP therapy and oral appliances are generally effective for snoring and sleep apnoea, wearing a mask on the face or a manipulative device in the mouth while sleeping is not the solution that most people first look for to prevent primary snoring or mild sleep apnoea. Typically snorers first seek a low cost, over-the-counter solution from a pharmacy or the Internet only to discover that the products on offer provide little benefit mainly because none deal effectively with the root cause of the problem; breathing through the mouth during sleep.
Nasal strips, sprays, and dilators are completely ineffective for the majority of people who start snoring when they switch from nose breathing to mouth breathing, yet few snorers seek professional help until the problem becomes more complex and develops into obstructive sleep apnoea (OSA), requiring CPAP therapy.
It is well recognized by all stakeholders that the biggest hurdle to growth in the CPAP industry is the difficulty in connecting with the undiagnosed OSA population despite the fact that potential patients are clearly identifiable by virtue of their call for help when sleeping: they snore. Snoring is the cardinal symptom of OSA, which makes snorers the largest identifiable pool of the undiagnosed OSA population, therefore the most effective strategy for sleep clinicians to connect with and bring potential OSA patients into the clinic for evaluation is to offer an OTC, low cost snoring product to meet the needs of primary snorers looking for a simple but effective solution.
Only when a sleep test is recommended by a GP do most sleep clinicians make their first contact with snorers, and given the resistance of most snorers to take their problem seriously enough to seek professional help, sleep clinicians waiting until people eventually walk in their door with a doctor’s prescription are like fishermen waiting for fish to leap into their boats.
And as the majority of snorers who present to sleep clinics have not developed OSA, or are unwilling to consider CPAP therapy or dental devices for relief from snoring or mild sleep apnoea, they leave. No sale! This is a classic case of consumer-provider disconnect and wasted marketing and advertising dollars.
The return on advertising expenditure to entice snorers to visit sleep clinics is even poorer if the valuable link to these potential CPAP consumers is effectively lost when they walk out the door, as the snorer has no motivation to return or maintain ongoing contact. When a snorer, as many do, eventually develops OSA, the clinic must invest further funds to entice them back again, or lose them to a competitor, if the opportunity to establish customer loyalty at the first and most costly contact is lost.
Offering an effective, low cost, OTC snoring product at sleep clinics, as an alternative to dental devices and CPAP, provides the clinician with the opportunity to initiate contact with a younger snoring demographic (who generally perceive sleep apnoea and CPAP therapy as issues for older people) and to nurture patient relationships during repeat visits for more product. Discussing sleeping issues, monitoring developing OSA and building a database of future OSA patients will ensure partnering clinicians are the provider-of-choice when the time for CPAP therapy arrives.
There is no better product for sleep clinics to add to their inventory than sleepQ+. Our new and unique innovation has multiple applications for sleep and breathing disorders. In addition to snoring, sleepQ+ also prevents mild sleep apnea, sleep disturbance, dry mouth, dehydration, sinus pressure, bad breath and nasal congestion, caused by mouth breathing during sleep.
Improving CPAP Therapy
sleepQ+ is also an effective method for preventing mouth breathing or venting during CPAP therapy and is preferred by patients over a chin strap because no force is used to maintain the lips together and the product causes no nasty side effects like headaches, skin redness or pressure marks often associated with chin straps. Pilot studies of sleepQ+ used in conjunction with CPAP therapy have shown a reduction in dryness in the mouth and throat (even with a full face mask), less visits to the bathroom during the night, lower CPAP pressure and no heavy sinus congestion in the morning due to breathing through the mouth. Users report a significant increase in well-being and compliance.
For patients with limited tolerance of CPAP, sleepQ+ is an excellent follow-on therapy each night to prevent snoring, dry mouth and sinus pressure caused by oral breathing. Visits to partnering clinics by CPAP patients (including competitors patients) to purchase sleepQ+ will provide regular opportunities for clinicians to discuss CPAP issues and introduce new products.
RespiraCorp’s unique marketing and distribution strategy is designed to help partnering sleep clinicians break through the barrier to the elusive undiagnosed OSA population and ensure a greater flow of patients to clinics for regular screening of OSA together with follow-up care and support at each step towards purchasing CPAP equipment.
sleepQ+ is registered with the TGA, HealthCanada and Medsafe NZ as a class 1 medical device.
Sleep clinicians and clinic managers are invited to contact us for further information, free sleepQ+ samples and to arrange a visit from one of our team for a confidential discussion regarding our product and partnering proposal.
RespiraCorp Pty Ltd Level 1 165 Walker Street North Sydney NSW 2060 Australia. Email: email@example.com Postal address: PO Box 674 Avalon, NSW Australia PH: +61 0414 600 141